文献速递临床试验与 GCP基础与转化研究组学、生物样本库与精准医学

二甲双胍联合可发酵纤维治疗重度肥胖伴胰岛素抵抗青少年的疗效:双盲随机对照试验研究方案

Efficacy of metformin and fermentable fiber combination therapy in adolescents with severe obesity and insulin resistance: study protocol for a double-blind randomized controlled trial.
PubMed 文献 · Trials · 2021-02-17

本方案为三臂平行双盲随机对照试验,纳入12-18岁肥胖、胰岛素抵抗且有2型糖尿病家族史的青少年,分别接受二甲双胍、可发酵纤维或两者联合治疗12个月。主要结局为胰岛素抵抗指数变化,并评估肠道微生物组组成与功能特征,以探索联合治疗的协同效应及机制。

要点

  • 比较二甲双胍、可发酵纤维及联合治疗对青少年胰岛素抵抗的代谢效应。
  • 主要结局为HOMA-IR变化,关键次要结局包括Matsuda指数、口服处置指数等。
  • 将分析粪便微生物组组成、短链脂肪酸和胆汁酸等宿主-微生物互作指标。

核心结论

  • 本研究将比较纤维与二甲双胍在肥胖青少年中的代谢获益,并确定两者是否协同改善胰岛素抵抗。

研究设计与样本

  • 平行三臂、双盲、随机对照试验,纳入12-18岁肥胖、胰岛素抵抗且有2型糖尿病家族史的青少年。
  • 干预分别为二甲双胍850 mg口服每日两次、可发酵纤维35 g/天或两者联合,疗程12个月。
  • 随访节点为基线、3、6、12个月,并在1和9个月进行电话随访。

关键数值与推荐

  • 主要结局为通过稳态模型评估的胰岛素抵抗指数变化。
  • 关键次要结局包括Matsuda指数、口服处置指数、BMI z评分及脂肪质量与去脂质量比值的变化。
  • 机制终点包括肥胖相关免疫、代谢和饱腹感标志物、体液代谢物、粪便微生物群组成、短链脂肪酸和胆汁酸。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accumulating evidence suggests that the metabolic effects of metformin and fermentable fibers are mediated, in part, through diverging or overlapping effects on the composition and metabolic functions of the gut microbiome. Pre-clinical animal models have established that the addition of fiber to metformin monotherapy improves glucose tolerance. However, possible synergistic effects of combination therapy (metformin plus fiber) have not been investigated in humans. Moreover, the underlying mechanisms of synergy have yet to be elucidated. The aim of this study is to compare in adolescents with obesity the metabolic effects of metformin and fermentable fibers in combination with those of metformin or fiber alone. We will also determine if therapeutic responses correlate with compositional and functional features of the gut microbiome. METHODS: This is a parallel three-armed, double-blinded, randomized controlled trial. Adolescents (aged 12-18 years) with obesity, insulin resistance (IR), and a family history of type 2 diabetes mellitus (T2DM) will receive either metformin (850 mg p.o. twice/day), fermentable fibers (35 g/day), or a combination of metformin plus fiber for 12 months. Participants will be seen at baseline, 3, 6, and 12 months, with a phone follow-up at 1 and 9 months. Primary and secondary outcomes will be assessed at baseline, 6, and 12 months. The primary outcome is change in IR estimated by homeostatic model assessment of IR; key secondary outcomes include changes in the Matsuda index, oral disposition index, body mass index z-score, and fat mass to fat-free mass ratio. To gain mechanistic insight, endpoints that reflect host-microbiota interactions will also be assessed: obesity-related immune, metabolic, and satiety markers; humoral metabolites; and fecal microbiota composition, short-chain fatty acids, and bile acids. DISCUSSION: This study will compare the potential metabolic benefits of fiber with those of metformin in adolescents with obesity, determine if metformin and fiber act synergistically to improve IR, and elucidate whether the metabolic benefits of metformin and fiber associate with changes in fecal microbiota composition and the output of health-related metabolites. This study will provide insight into the potential role of the gut microbiome as a target for enhancing the therapeutic efficacy of emerging treatments for T2DM prevention. TRIAL REGISTRATION: ClinicalTrials.gov NCT04578652 . Registered on 8 October 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Deehan EC, Colin-Ramirez E, Triador L, et al. Efficacy of metformin and fermentable fiber combination therapy in adolescents with severe obesity and insulin resistance: study protocol for a double-blind randomized controlled trial. Trials. 2021. PMID: 33596993. doi:10.1186/s13063-021-05060-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。